

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
YESHIVA UNIVERSITY	04/07/1997
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	08153796
Patent Number:	5604202
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director, DEITR, NIH
Total Attachments: 1	
source=08153796-p0001 - p0002#page2.tif	

500548281

PATENT  
REEL: 021006 FRAME: 0320

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention:

Invention Title:       USE OF GROWTH FACTORS TO TREAT  
                          DRUG-INDUCED NEUROPATHY

Inventor(s):            Dr. John A. Kessler  
                          Dr. Stuart C. Apfel

US Patent Application  
Serial No.:            08/153,796

Filing Date:           11/17/93

U.S. Patent No.       5,604,202

Issue Date:            2/18/97

Title:                   USE OF GROWTH FACTORS TO TREAT  
                          DRUG-INDUCED NEUROPATHY

Country, if other than the United States: Japan PCT/US93/05203

This license will extend to all divisions or continuations of the patent application and all patents or re-issues which may be granted thereon.

This subject invention was made with government support from Grant/Contract No. NIH 5R01ES05752-04 awarded by the National Institutes of Health.

Principal rights to this subject invention have been left with the Licensor: The Albert Einstein College of Medicine of Yeshiva University subject to the provisions of Title 35 USC 200-212, 37 CFR 401, and 45 CFR 8.

Signed: \_\_\_\_\_

Date: 4/29/97

Typed Name: Dr. Sheldon E. Socol

Vice President for Business Affairs

SEAL

PATENT

RECORDED: 05/23/2008

REEL: 021006 FRAME: 0321